Literature DB >> 28163032

Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.

Matthew Truong1, Gary Hollenberg2, Eric Weinberg2, Edward M Messing3, Hiroshi Miyamoto3, Thomas P Frye4.   

Abstract

PURPOSE: We determined whether Gleason pattern 4 architecture impacts tumor visibility on multiparametric magnetic resonance imaging and correlates with final histopathology.
MATERIALS AND METHODS: A total of 83 tumor foci were identified in 22 radical prostatectomy specimens from patients with a prior negative biopsy who underwent magnetic resonance/ultrasound fusion biopsy followed by radical prostatectomy from January 2015 to July 2016. A genitourinary pathologist rereviewed tumor foci for Gleason architectural subtype. Each prostate imaging reporting and data system category 3 to 5 lesion on multiparametric magnetic resonance imaging was paired with its corresponding pathological tumor focus. Univariable and multivariable analyses were performed to determine predictors of tumor visibility.
RESULTS: Of the 83 tumor foci identified 26 (31%) were visible on multiparametric magnetic resonance imaging, 33 (40%) were Gleason score 3+3 and 50 (60%) were Gleason score 3+4 or greater. Among tumor foci containing Gleason pattern 4, increasing tumor size and noncribriform predominant architecture were the only independent predictors of tumor detection on multivariable analysis (p = 0.002 and p = 0.011, respectively). For tumor foci containing Gleason pattern 4, 0.5 cm or greater, multiparametric magnetic resonance imaging detected 10 of 13 (77%), 5 of 14 (36%) and 9 of 10 (90%) for poorly formed, cribriform and fused architecture, respectively (p = 0.01). The size threshold for the detection of cribriform tumors was higher than that of other architectural patterns. Furthermore, cribriform pattern was identified more frequently on systematic biopsy than on targeted biopsy.
CONCLUSIONS: Reduced visibility of cribriform pattern on multiparametric magnetic resonance imaging has significant ramifications for prostate cancer detection, surveillance and focal therapy.
Copyright © 2017 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biopsy; magnetic resonance imaging; prostatic neoplasms

Mesh:

Year:  2017        PMID: 28163032     DOI: 10.1016/j.juro.2017.01.077

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  21 in total

1.  Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer.

Authors:  Elmira Hassanzadeh; Francesco Alessandrino; Olutayo I Olubiyi; Daniel I Glazer; Robert V Mulkern; Andriy Fedorov; Clare M Tempany; Fiona M Fennessy
Journal:  Abdom Radiol (NY)       Date:  2018-05

2.  Diagnostic performance of 68Ga-PSMA PET/CT for identification of aggressive cribriform morphology in prostate cancer with whole-mount sections.

Authors:  Jie Gao; Chengwei Zhang; Qing Zhang; Yao Fu; Xiaozhi Zhao; Mengxia Chen; Bing Zhang; Danyan Li; Jiong Shi; Feng Wang; Hongqian Guo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-25       Impact factor: 9.236

Review 3.  The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer.

Authors:  Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2017-07       Impact factor: 3.092

Review 4.  Artificial intelligence at the intersection of pathology and radiology in prostate cancer.

Authors:  Stephnie A Harmon; Sena Tuncer; Thomas Sanford; Peter L Choyke; Barış Türkbey
Journal:  Diagn Interv Radiol       Date:  2019-05       Impact factor: 2.630

5.  Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?

Authors:  Cheyenne Williams; Michael Ahdoot; Michael A Daneshvar; Christian Hague; Andrew R Wilbur; Patrick T Gomella; Joanna Shih; Nabila Khondakar; Nitin Yerram; Sherif Mehralivand; Sandeep Gurram; Minhaj Siddiqui; Paul Pinsky; Howard Parnes; Maria Merino; Bradford Wood; Baris Turkbey; Peter A Pinto
Journal:  J Urol       Date:  2021-08-26       Impact factor: 7.450

6.  Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Authors:  Anwar R Padhani; Jeffrey Weinreb; Andrew B Rosenkrantz; Geert Villeirs; Baris Turkbey; Jelle Barentsz
Journal:  Eur Urol       Date:  2018-06-13       Impact factor: 20.096

7.  Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer.

Authors:  Simpa S Salami; Jeremy B Kaplan; Srinivas Nallandhighal; Mandeep Takhar; Jeffrey J Tosoian; Matthew Lee; Junhee Yoon; Daniel H Hovelson; Komal R Plouffe; Samuel D Kaffenberger; Edward M Schaeffer; R Jeffrey Karnes; Tamara L Lotan; Todd M Morgan; Arvin K George; Jeffrey S Montgomery; Matthew S Davenport; Sungyong You; Scott A Tomlins; Nicole E Curci; Hyung L Kim; Daniel E Spratt; Aaron M Udager; Ganesh S Palapattu
Journal:  JCO Precis Oncol       Date:  2019-06-12

8.  Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging.

Authors:  Stephanie A Harmon; G Thomas Brown; Thomas Sanford; Sherif Mehralivand; Joanna H Shih; Sheng Xu; Maria J Merino; Peter L Choyke; Peter A Pinto; Bradford J Wood; Jesse K McKenney; Baris Turkbey
Journal:  Quant Imaging Med Surg       Date:  2020-02

9.  Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer.

Authors:  Masashi Kato; Akihiro Hirakawa; Yumiko Kobayashi; Akiyuki Yamamoto; Yushi Naito; Kosuke Tochigi; Tomoyasu Sano; Shohei Ishida; Yasuhito Funahashi; Takashi Fujita; Yoshihisa Matsukawa; Ryohei Hattori; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-08-03       Impact factor: 3.402

Review 10.  Current Understanding and Management of Intraductal Carcinoma of the Prostate.

Authors:  Bryden Considine; Adebowale Adeniran; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.